Literature DB >> 22072027

Prostate cancer: who will win the CRPC drug race?

Melanie Clyne.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072027     DOI: 10.1038/nrurol.2011.157

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Authors:  Roberto Pili; Michael Häggman; Walter M Stadler; Jeffrey R Gingrich; Vasileios J Assikis; Anders Björk; Orjan Nordle; Goran Forsberg; Michael A Carducci; Andrew J Armstrong
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Authors:  M D Michaelson; J Bellmunt; G R Hudes; S Goel; R J Lee; P W Kantoff; C A Stein; P Lardelli; I Pardos; C Kahatt; A Nieto; M Cullell-Young; N L Lewis; M R Smith
Journal:  Ann Oncol       Date:  2011-09-19       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.